Yaqrit is developing treatments for liver disease. Twenty years of work in liver disease has led to a family of breakthroughs, now combined with experienced management to bring new treatments to liver patients around the world.
Our first programmes are for severely ill patients - with cirrhosis or Acute-on-Chronic Liver Failure (ACLF). We plan to broaden our approach to include patients with complication of cirrhosis, Non-Alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), which affects more than 25% of populations in developed economies*.
*The Burden of Liver Disease in Europe: A review of available epidemiological data, Blachier et.al, J Hepatol. 2013 Mar;58(3):593-608 .
Daniel Green, MSc has been CEO of Yaqrit. Previously he was CEO of Phagenesis Ltd whose sale to Nestlé was announced Sep 2016 - See Daniel Green at LinkedIn.
Prof Rajiv Jalan, CSO and founder, Professor of Hepatology Head, Liver Failure Group Institute of Hepatology, University College London, Editor in Chief of the Journal of Hepatology and a serial inventor in liver disease - See Rajiv Jalan at LinkedIn.
Giovanni Rizzo, PhD joined Yaqrit as VP from Intercept Pharma (Nasdaq: ICPT) and his experience spans both molecular biology and medical device development - See Giovanni Rizzo at LinkedIn.
Karen Church PhD has been head of quality and regulatory since 2015 and previously held senior positions at ex- Pfizer and at Ocera Therapeutics (Nasdaq OCRX) - see Karen Church at LinkedIn.
Hiep Huatan PhD is head of manufacturing and formulation and previously held senior roles at Pfizer and several other companies - see Hiep Huatan at LinkedIn.